May 19, 2014

Aerocrine, a medical technology company with a focus on improving the treatment of patients with inflamed airways, announced that Health Care Services Corp. will begin covering fractional exhaled Nitric Oxide (FeNO) testing, which is used to diagnose and manage asthma.

March 10, 2014

Aerocrine AB, a medical products company focused on improved management and care of patients with such inflammatory airway diseases as asthma, has announced that a new randomized clinical trial shows lower incidence of asthma exacerbations and increased asthma control with Fractional exhaled Nitric Oxide (FeNO)-guided anti-inflammatory treatment.

March 28, 2010

Rite Aid and the American Academy of Allergy, Asthma and Immunology again have partnered to...